Navigation Links
CuraGen to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and CR011-vcMMAE Phase II Trial Results on November 3, 2008

BRANFORD, Conn., Oct. 29 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced today that Company executives will be holding a conference call and webcast at 11:00 a.m. ET on Monday, November 3, 2008 following the release of third quarter 2008 financial results and to review preliminary data from CuraGen's Phase II clinical trial evaluating CR011-vcMMAE for the treatment of advanced melanoma.

Data from CuraGen's Phase II trial of CR011-vcMMAE will be presented during an oral session at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer (iSBTc), being held October 31 - November 2, 2008, in San Diego, CA. The results will be presented on Saturday, November 1, 2008, at 3:15 p.m. Pacific time in the Tumor Targeting Monoclonal Antibodies session.

Press releases detailing the financial results and the Phase II data on CR011-vcMMAE will be issued prior to market open on Monday, November 3, 2008.

Conference Call and Webcast Details

Date: Monday, November 3, 2008

Time: 11:00 a.m. ET

Dial-in: 877-272-5391 (domestic)

706-758-4315 (international)

Passcode: 71190212

Webcast: Accessible at

A replay of the conference call and webcast will be available beginning at 2:00 p.m. ET on Monday, November 3, 2008 through Wednesday, December 3, 2008 by dialing 800-642-1687 (domestic) or 706-645-9291 (international). The passcode for the replay is 71190212. An archive of the webcast will also be available for 30 days at

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit



Sean Cassidy

Vice President and Chief Financial Officer

(203) 871-4400

Glenn Schulman, PharmD

Director of Medical Communications

(888) 436-6642

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
11. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
Post Your Comments:
(Date:12/1/2015)... 01, 2015 ... the "Medium Molecular Weight Polyisobutylene Market ... Other Applications - Global Industry Analysis, Size, ... 2023" report to their offering. ... addition of the "Medium Molecular Weight ...
(Date:12/1/2015)... CLEVELAND , Dec. 1, 2015   ... innovation firm, today announced the publication of a ... Entering the Direct-to-Consumer Medical Market". The whitepaper gives ... roadmap for successfully penetrating this lucrative segment. ... purchase healthcare products to manage their own health, ...
(Date:12/1/2015)... 1, 2015 Array BioPharma Inc. ... its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public ... through a webcast on the Array BioPharma ... --> , ...
Breaking Medicine Technology:
(Date:12/1/2015)... (PRWEB) , ... December 02, 2015 , ... ... research “ Gastrointestinal events and association with initiation of treatment for osteoporosis ”. ... the use of pharmacological treatment in patients diagnosed with osteoporosis. Based on a ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... its acquisition by Jordan Industries International, LLC (“JII”). , With support from JII, ... and maintenance services to hospitals, surgery centers, clinics, research labs and medical facilities ...
(Date:12/1/2015)... ... , ... According to an article published on November 16th by ... U.S. Department of Health and Human Services, claiming that any states which do not ... clause in the law prohibiting the denial of coverage for pre-existing conditions. The article ...
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center Jacksonville ... is the only hospital in the region providing what is known as the ... pacing patients were revealed recently at a medical conference and published in The ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of ... has been named by MedEsthetics magazine as the Best Single Physician Practice in the ... the many elite aesthetic physicians honored by the industry publication. , Dr. Vitenas ...
Breaking Medicine News(10 mins):